Allen Hu Annexon, Apellis, Bayer, Clearside, Genentech, Janssen, Oculis, Outlook Therapeutics, Regeneron, Roche, Stealth, Code C (Consultant/Contractor), 4DMT, Abbvie, Acelyrin, Alexion, Alimera, Annexin, Annexon, Apellis, Ashvattha, Aviceda, Bayer, Boehringer Ingelheim, Chengdu Kanghong, Clearside, Cognition, Curacle, EyeBioTech, EyePoint, Genentech, Graybug, IONIS, IVERIC bio, Janssen, Kodiak, LMRI, Lupin, Lumithera, Neurotech, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Ophthotech, Opthea, Outlook Therapeutics, Oxurion, Regeneron, RegenXBio, Rezolute, Roche, Sandoz, Shanghai Henlius, Smilebiotek Zhuhai, Stealth, UNITY, Code F (Financial Support), Apellis, Genentech, Iveric Bio. Advisory/Data , Code R (Recipient), Clearside, Code R (Recipient);
Rachel Teneralli Johnson & Johnson Innovative Medicine, Code E (Employment);
Rachelle Rodriguez Johnson & Johnson Innovative Medicine, Code E (Employment);
Alyshah Sultan Johnson & Johnson Innovative Medicine, Code E (Employment);
Colleen Garey Panaglo, which received funding from Johnson & Johnson Innovative Medicine for this analysis, Code E (Employment);
Rose Ong Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson and Johnson, Code E (Employment);
Jessica Ackert Johnson & Johnson Innovative Medicine, Code E (Employment)